Beacon Pointe Advisors LLC Sells 607,423 Shares of Pfizer Inc. $PFE

Beacon Pointe Advisors LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 40.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 909,383 shares of the biopharmaceutical company’s stock after selling 607,423 shares during the quarter. Beacon Pointe Advisors LLC’s holdings in Pfizer were worth $22,043,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter worth $27,000. Curio Wealth LLC grew its position in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new position in shares of Pfizer during the 1st quarter worth about $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the second quarter valued at about $29,000. Finally, Evelyn Partners Asset Management Ltd bought a new stake in shares of Pfizer in the second quarter valued at about $33,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $25.31 on Tuesday. The firm has a market cap of $143.88 billion, a price-to-earnings ratio of 13.46, a PEG ratio of 0.81 and a beta of 0.54. The company has a 50 day moving average of $25.03 and a 200-day moving average of $24.62. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 7th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend was Friday, November 7th. Pfizer’s payout ratio is currently 100.00%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Scotiabank began coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.39.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.